CY1124939T1 - Συζευγματα στανοζολολης και υαλουρονικου οξεος - Google Patents
Συζευγματα στανοζολολης και υαλουρονικου οξεοςInfo
- Publication number
- CY1124939T1 CY1124939T1 CY20221100093T CY221100093T CY1124939T1 CY 1124939 T1 CY1124939 T1 CY 1124939T1 CY 20221100093 T CY20221100093 T CY 20221100093T CY 221100093 T CY221100093 T CY 221100093T CY 1124939 T1 CY1124939 T1 CY 1124939T1
- Authority
- CY
- Cyprus
- Prior art keywords
- hyaluronic acid
- stanozolol
- hydrogels
- acid salt
- stanzolol
- Prior art date
Links
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 7
- 229920002674 hyaluronan Polymers 0.000 title abstract 4
- 229960003160 hyaluronic acid Drugs 0.000 title abstract 4
- LKAJKIOFIWVMDJ-IYRCEVNGSA-N Stanazolol Chemical compound C([C@@H]1CC[C@H]2[C@@H]3CC[C@@]([C@]3(CC[C@@H]2[C@@]1(C)C1)C)(O)C)C2=C1C=NN2 LKAJKIOFIWVMDJ-IYRCEVNGSA-N 0.000 abstract 3
- 239000000017 hydrogel Substances 0.000 abstract 3
- 229960000912 stanozolol Drugs 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000006071 cream Substances 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 239000006260 foam Substances 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000006210 lotion Substances 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/43—Hormones, e.g. dexamethasone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Materials For Medical Uses (AREA)
Abstract
Αποκαλύπτονται συζεύγματα μεταξύ στανοζολόλης και υαλουρονικού οξέος ή ενός άλατος υαλουρονικού οξέος, που χαρακτηρίζονται από το ότι η στανοζολόλη συζευγνύεται με την καρβοξυλική ομάδα του υαλουρονικού οξέος ή το άλας υαλουρονικού οξέος μέσω ενός αποστάτη που σχηματίζει έναν εστερικό δεσμό με την υδροξυλική ομάδα της στανοζολόλης και έναν δεσμό εστέρα ή αμιδίου με την καρβοξυλική ομάδα του υαλουρονικού οξέος ή το άλας υαλουρονικού οξέος. Τα συζεύγματα σύμφωνα προς την εφεύρεση είναι χρήσιμα για την παρασκευή υδρογελών, ενέσιμων υδρογελών, υδρογελών για εξωτερική χρήση, κρεμών, λοσιόν, αφρών, υδατικών διαλυμάτων για ενδοαρθρική χρήση, γαλακτωμάτων για οφθαλμική χρήση, οφθαλμικών σταγόνων, ικριωμάτων, τεχνητών ιστών και μέσων καλλιέργειας.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102018000003841A IT201800003841A1 (it) | 2018-03-21 | 2018-03-21 | Coniugati di stanozololo e acido ialuronico |
PCT/IB2019/052034 WO2019180548A1 (en) | 2018-03-21 | 2019-03-13 | Conjugates of stanozolol and hyaluronic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124939T1 true CY1124939T1 (el) | 2023-01-05 |
Family
ID=62597894
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100093T CY1124939T1 (el) | 2018-03-21 | 2022-02-03 | Συζευγματα στανοζολολης και υαλουρονικου οξεος |
Country Status (21)
Country | Link |
---|---|
US (1) | US11013813B2 (el) |
EP (1) | EP3768729B1 (el) |
JP (1) | JP7301392B2 (el) |
KR (1) | KR20200135824A (el) |
CN (1) | CN111868097B (el) |
AU (1) | AU2019240175B2 (el) |
CA (1) | CA3094277A1 (el) |
CY (1) | CY1124939T1 (el) |
DK (1) | DK3768729T3 (el) |
ES (1) | ES2908887T3 (el) |
HR (1) | HRP20220166T1 (el) |
HU (1) | HUE058230T2 (el) |
IL (1) | IL277319B2 (el) |
IT (1) | IT201800003841A1 (el) |
LT (1) | LT3768729T (el) |
MX (1) | MX2020009680A (el) |
PL (1) | PL3768729T3 (el) |
PT (1) | PT3768729T (el) |
RS (1) | RS63033B1 (el) |
SI (1) | SI3768729T1 (el) |
WO (1) | WO2019180548A1 (el) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6107289A (en) * | 1992-04-21 | 2000-08-22 | The Schepens Eye Research Institute, Inc. | Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β |
AU2005219733C1 (en) * | 2004-03-05 | 2010-12-16 | Denki Kagaku Kogyo Kabushiki Kaisha | Hyaluronic acid-methotrexate conjugate |
ITMI20061609A1 (it) * | 2006-08-10 | 2008-02-11 | Acme Drugs Srl | Formulazioni intrasinoviali di stanozololo |
US20090202645A1 (en) | 2008-02-08 | 2009-08-13 | Acme Drugs S.R.L. | Intrasynovial formulations of stanozolol |
CN104603156B (zh) * | 2012-09-05 | 2016-10-26 | 中外制药株式会社 | 引入有氨基酸和甾基的透明质酸衍生物 |
-
2018
- 2018-03-21 IT IT102018000003841A patent/IT201800003841A1/it unknown
-
2019
- 2019-03-13 AU AU2019240175A patent/AU2019240175B2/en active Active
- 2019-03-13 IL IL277319A patent/IL277319B2/en unknown
- 2019-03-13 DK DK19721024.8T patent/DK3768729T3/da active
- 2019-03-13 CA CA3094277A patent/CA3094277A1/en active Pending
- 2019-03-13 MX MX2020009680A patent/MX2020009680A/es unknown
- 2019-03-13 CN CN201980020203.8A patent/CN111868097B/zh active Active
- 2019-03-13 PT PT197210248T patent/PT3768729T/pt unknown
- 2019-03-13 JP JP2020550101A patent/JP7301392B2/ja active Active
- 2019-03-13 HU HUE19721024A patent/HUE058230T2/hu unknown
- 2019-03-13 SI SI201930172T patent/SI3768729T1/sl unknown
- 2019-03-13 US US16/981,810 patent/US11013813B2/en active Active
- 2019-03-13 PL PL19721024T patent/PL3768729T3/pl unknown
- 2019-03-13 LT LTEPPCT/IB2019/052034T patent/LT3768729T/lt unknown
- 2019-03-13 WO PCT/IB2019/052034 patent/WO2019180548A1/en unknown
- 2019-03-13 KR KR1020207030033A patent/KR20200135824A/ko not_active Application Discontinuation
- 2019-03-13 HR HRP20220166TT patent/HRP20220166T1/hr unknown
- 2019-03-13 RS RS20220225A patent/RS63033B1/sr unknown
- 2019-03-13 EP EP19721024.8A patent/EP3768729B1/en active Active
- 2019-03-13 ES ES19721024T patent/ES2908887T3/es active Active
-
2022
- 2022-02-03 CY CY20221100093T patent/CY1124939T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021518378A (ja) | 2021-08-02 |
IL277319A (en) | 2020-10-29 |
IL277319B2 (en) | 2024-02-01 |
KR20200135824A (ko) | 2020-12-03 |
EP3768729A1 (en) | 2021-01-27 |
CA3094277A1 (en) | 2019-09-26 |
US11013813B2 (en) | 2021-05-25 |
MX2020009680A (es) | 2020-10-12 |
RS63033B1 (sr) | 2022-04-29 |
HRP20220166T1 (hr) | 2022-04-29 |
WO2019180548A1 (en) | 2019-09-26 |
SI3768729T1 (sl) | 2022-04-29 |
AU2019240175B2 (en) | 2024-05-02 |
IT201800003841A1 (it) | 2019-09-21 |
JP7301392B2 (ja) | 2023-07-03 |
CN111868097B (zh) | 2023-06-06 |
US20210038735A1 (en) | 2021-02-11 |
EP3768729B1 (en) | 2022-01-26 |
DK3768729T3 (da) | 2022-02-07 |
PT3768729T (pt) | 2022-03-11 |
IL277319B1 (en) | 2023-10-01 |
LT3768729T (lt) | 2022-05-25 |
HUE058230T2 (hu) | 2022-07-28 |
CN111868097A (zh) | 2020-10-30 |
ES2908887T3 (es) | 2022-05-04 |
AU2019240175A1 (en) | 2020-11-12 |
PL3768729T3 (pl) | 2022-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124575T1 (el) | Πολυμερικα συστηματα χορηγησης μακρας δρασης | |
BRPI0909630B8 (pt) | composição em suspensão aquosa particularmente adequada para injeção dentro do olho | |
AR106367A1 (es) | Composiciones de polisacáridos entrecruzables in situ y usos de las mismas | |
CY1121336T1 (el) | Νεα θειικη δεξτρανη | |
CY1124718T1 (el) | Ανθεκτικο στη διασπαση υαλουρονικο χαμηλου μοριακου βαρους με σταυροδεσμους | |
BR112016006197A2 (pt) | método para produzir heteromultímero de polipeptídeo | |
BR112018013979A2 (pt) | composições em gel para liberação transdérmica para maximizar as concentrações de fármacos no estrato córneo e no soro e métodos de uso dos mesmos | |
MX2023003124A (es) | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. | |
AR107967A1 (es) | Ácido hialurónico modificado, método para su preparación y usos del mismo | |
BR112015015123A2 (pt) | composição cosmética, método para aprimoramento da característica de pele e uso de uma composição | |
CO2019008987A2 (es) | Mejoras en o con respecto a compuestos orgánicos | |
BR112015032200A2 (pt) | conjugado anticorpo-droga com estabilidade melhorada, método de preparação, composição farmacêutica e uso do mesmo | |
BR112014007367A2 (pt) | processo para despolimerizar um polissacarídeo, polissacarídeo, e, uso de um polissacarídeo | |
MX2016015211A (es) | Formulaciones topicas y usos de las mismas. | |
BR112015016817A8 (pt) | métodos para derivar um sacarídeo, para conjugar um derivado de sacarídeo e para incitar uma resposta imune em um mamífero, derivado de sacarídeo, conjugado de um derivado de sacarídeo, composição farmacêutica, e, uso de um conjugado ou composição farmacêutica | |
CY1124538T1 (el) | Χρηση prg4 για τη βελτιωση της δυναμικης οπτικης οξυτητας και εκτροπων υψηλοτερης ταξης | |
BR112013033303A2 (pt) | métodos para a produção de uma composição cosmética compreendendo leucolectina e usos da mesma | |
CR20210161A (es) | Composiciones farmacéuticas semisólidas de base oleosa conteniendo pirfenidona para su aplicación en la reparación tisular | |
WO2015017340A3 (en) | Low swell tissue adhesive and sealant formulations | |
CY1124939T1 (el) | Συζευγματα στανοζολολης και υαλουρονικου οξεος | |
AU2017373587A1 (en) | Method for producing transparent preparations for examination by light microscopy | |
MX2018005903A (es) | Moléculas bifuncionales que contienen peg para uso en la inhibición de cataratas y presbicia. | |
CY1124930T1 (el) | Διεργασια για την παρασκευη στειρων οφθαλμικων υδατικων εναιωρηματων νανοκρυσταλλων μορφης α προπιονικης φλουτικαζονης | |
BR112015032669A2 (pt) | composição, uso de pelo menos um pigmento revestido e método de cuidado cosmético | |
AR099680A1 (es) | Muteínas mejoradas de factor viii de coagulación |